Today, investors did not wait for the expected rebound.
In early trading, the three major A-share indexes opened slightly higher, but the Shanghai index quickly fell below 2900 points in early trading. Then, the three indexes started a counterattack and all turned red at noon. However, in the afternoon, the market returned to the downward trend, and the Shanghai index fell below 2900 points again and continued to decline. As of the close, the Shanghai index fell 1.44% to 288643 points, the Shenzhen composite index fell 1.66% to 1020664 points, and the gem index fell 0.85% to 215051 points.
In terms of individual stocks, nearly 4000 stocks in the two cities fell. In terms of transactions, the full day turnover of Shanghai and Shenzhen markets was 838.8 billion yuan. Northbound funds bought a net 1.543 billion yuan against the trend throughout the day and sold nearly 1.8 billion yuan in the morning; Among them, the Shanghai Stock connect net sold 278 million yuan and the Shenzhen Stock connect net bought 1.821 billion yuan.
In terms of sectors, only a small number of sectors in the two cities rose, and the increase was very small. The heparin concept rose by nearly 2%, and several sectors such as dexamethasone, tax-free concept, tax rebate store, Ning combination and super brand were popular. The sectors with large decline include textile and garment, transgenic, human brain engineering, coal industry, securities, shipbuilding, brokerage concept, mining industry, chemical raw materials, computer equipment, tire pressure monitoring, state-owned assets cloud concept, etc., with a decline of more than 5%P align = “center” Sinopharm group Austrian strain covid-19 inactivated vaccine obtained clinical approval p align = “center” China National Medicines Corporation Ltd(600511) straight up limit
On the afternoon of the 26th, China National Medicines Corporation Ltd(600511) rose the daily limit in a straight line, the amount of sealed orders was nearly 300 million yuan, and China National Accord Medicines Corporation Ltd(000028) , Shanghai Shyndec Pharmaceutical Co.Ltd(600420) followed.
In terms of news, according to China biological news, on April 26, 2022, the covid-19 virus inactivated vaccine of Sinopharm China biological Omicron variant (hereinafter referred to as Austrian strain) obtained the clinical approval of the State Food and drug administration.
It is reported that Sinopharm China Bio introduced the Omicron variant strain from the University of Hong Kong for the first time on the basis of the prototype covid-19 inactivated vaccine that has been listed in the early stage and the research and development of beta and delta variant inactivated vaccine. On December 9, 2021, Sinopharm China Bio quickly launched the research and development of Austrian strain inactivated vaccine.
On March 3, 2022, Beijing Institute of biological products and Wuhan Institute of biological products determined the clinical scheme and relevant details with Hong Kong research institutions. On March 26 and 30, they obtained the verification qualification report of China Institute of drug and food control respectively. On April 1, they submitted clinical application materials to the Hong Kong Department of health, obtained ethical approval on April 12 and clinical research approval on April 13, It has become the first inactivated vaccine of Omicron strain approved for clinical use in the world.
On April 26, the inactivated vaccine of Omicron variant covid-19 virus of Beijing Institute of biological products of China obtained the clinical approval issued by the State Food and Drug Administration of China. In the form of randomized, double-blind and cohort study, China biology will conduct a sequential immune clinical study among people aged 18 and over who have completed 2 or 3 doses of covid-19 vaccine to evaluate the safety and immunogenicity of inactivated covid-19 virus vaccine of Omicron variant.
As of the closing, China National Medicines Corporation Ltd(600511) reported 27.57 yuan / share, with a total market value of 20.8 billion yuan China National Accord Medicines Corporation Ltd(000028) reported 29.19 yuan / share, up 8.31%, with a total market value of 12.5 billion yuan Shanghai Shyndec Pharmaceutical Co.Ltd(600420) reported 9 yuan / share, up 4.77%, with a total market value of 9.243 billion yuan.
central bank’s response to market fluctuations: mainly affected by investor expectations and sentiment
Yesterday, the A-share market fell sharply, and the Shanghai stock index fell below the integer mark of 3000 points, down 5.13%, the largest one-day decline in more than two years since February 3, 2020, and all major industry sectors fell across the board.
On April 26, according to the people’s Bank of China, the relevant person in charge of the people’s Bank of China pointed out in an interview with the financial times on the current financial market situation that we are concerned about some fluctuations in the financial market recently, which are mainly affected by the expectations and emotions of investors. At present, China’s economic fundamentals are sound, the potential for endogenous economic growth is huge, and substantial progress has been made in preventing and resolving financial risksP align= “center” screenshot source: official account of the people’s Bank of China
The financial system implements the decisions and arrangements of the CPC Central Committee and the State Council, coordinates the epidemic prevention and control and economic and social development, supports smooth logistics and promotes the stability of the industrial chain and supply chain, and minimizes the impact of the epidemic on economic and social development.
On April 26, Shanghai Securities Association, Futures Association and Fund Association jointly issued the notice on matters related to further improving epidemic prevention and control and serving economic development in Shanghai Securities and futures fund industry (hereinafter referred to as the notice). The circular said that in order to further coordinate the epidemic prevention and control, market stability and services to support Shanghai’s economic development, Shanghai’s securities and futures fund operating institutions and all employees should strengthen their confidence and remain determined; Fulfill the main responsibilities and make relevant work arrangements; Firmly maintain market stability and give full play to the positive role of industry institutionsP align = “center” screenshot source: Shanghai Securities News
The notice points out that professional institutional investors should fully reflect the responsibility, practice and adhere to the concept of long-term investment and value investment. Based on the in-depth analysis of enterprise fundamentals, make medium and long-term layout, firmly hold, actively play the role of capital market value discoverer and operation stabilizer, enhance market confidence and lay a solid foundation for the stable development of the market.
In terms of serving the real economy, the circular pointed out that first of all, we should give full play to the capital intermediary function and take the initiative to meet the financing needs of enterprises in key industries. Meet the financing needs of biomedical health enterprises such as covid-19 vaccine, rapid detection reagent and special drugs, customize a comprehensive financial scheme, and support the R & D and industrialization of covid-19 virus prevention and control innovative products. We will increase financing support for enterprises in transportation, commerce and retail, cultural tourism, catering and other industries greatly affected by the epidemic, and help enterprises return to work and production in an orderly manner. We will implement detailed financial relief, strengthen special investment services, increase support for private enterprises, small, medium-sized and micro enterprises, expand the coverage of inclusive financial services, and help enterprises tide over difficulties.
Secondly, give full play to the advantages of risk management and help enterprises reduce business risks. Earnestly perform the duties of the trustee, actively do a good job in bond risk monitoring and early warning, strengthen communication and coordination with investors, and assist the issuer to overcome difficulties by extending the term and adjusting the repayment of principal and interest. Comprehensively provide risk management tools covering interest rate, credit, exchange rate, commodities and other assets to help enterprises cope with epidemic situations and market price fluctuations, and improve their ability to prevent and resolve production and operation risks.
In addition, we should strengthen financial innovation and provide services to support the development of the real economy. Guided by the national strategy, actively improve the innovation ability of products and services, continue to increase investment in pension investment, responsible investment, independent innovation, green environmental protection and other fields, and actively create investment science and innovation enterprise products. Learn from the mature practice of “insurance + futures” business combination, strengthen the coordination and cooperation between the securities fund futures industry and other industries, realize resource sharing in information, capital and talents, enhance the ability to serve large customers and leading enterprises, and further enhance the quality and efficiency of serving the real economy.
